It is with a heavy heart that Springer Nature and Molecular Neurodegeneration say farewell to our long-serving co-Editor-in-Chief, Dr. Huaxi Xu. On October 14, 2022, Dr. Xu passed away after his brave battle against cancer, leaving behind a legacy of groundbreaking research in neurodegenerative disease, exemplary editorship, and undeniable leadership.
In the seventeen years of publication, Dr. Xu and Dr. Bu have raised Molecular Neurodegeneration to be a leading open-access neuroscience journal. This page is in commemoration of Dr. Xu’s work, life, and legacy. We invite friends, family, editors, authors, and reviewers alike to leave any notes or pictures. Please email Molecular Neurodegeneration’s Associate Publisher, Anastasiya Netrunenko (anastasiya.netrunenko@springernature.com) with your messages for and pictures with Huaxi.
Molecular Neurodegeneration presents a new thematic series, collating reviews which present and evaluate the challenges for the next decade of research into Alzheimer's disease.
Edited by Guojun Bu, Alison Goate and Todd Golde. The collection can be read here.
26 January 2023
21 January 2023
The leading open access journal in the field of neurosciences, Molecular Neurodegeneration encompasses all aspects of neurodegeneration research at the molecular and cellular levels.
Citation Impact
18.879 - 2-year Impact Factor (2021)
15.024 - 5-year Impact Factor (2021)
2.702 - Source Normalized Impact per Paper (SNIP)
4.731 - SCImago Journal Rank (SJR)
Speed
20 days to first decision for all manuscripts (Median)
54 days to first decision for reviewed manuscripts only (Median)
Usage
1,034,660 downloads (2021)
1,462 Altmetric mentions (2021)
Molecular Neurodegeneration